Compositions that include cannabinoids other than tetrahydrocannabinol (THC), such as cannabigerol (CBG) in combination with tetrahydrocannabinol (THC) or formulated to be combined with THC, and methods of preparation and use thereof are described. The compositions may be useful to reduce the risk of THC-induced anxiety and/or to produce a different intoxicating effect compared to THC alone.

The subject invention relates to a therapeutic patch, its manufacture and use wherein the patch comprises: a fabric layer made of synthetic fibers stretchable in both directions along a substantially orthogonal transverse axis of the patch, an adhesive layer on said face side of the base layer, an active agent dispersed in said adhesive layer, and optionally, a penetration enhancing agent in said adhesive layer.

Preparation of cannabinoid formulations containing: 9-tetrahydrocannabinol (9-THC), 8-tetrahydrocannabinol (8-THC), 9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

A system and method for processing hemp plants is disclosed. The process is capable of processing whole cannabis plants for producing multiple useful products. A pair of hammermills are used in series in order to produce an extractable cannabis material for obtaining cannabinoids, such as CBD, and a fiber product. The hurds contained in the cannabis plant material are controlled and fractionated during the process for allowing high throughput.

A composition includes a first compound having general formula I and a second compound for use in the synergistic activation of AMPK. A method of using the composition in the synergistic activation of AMPK is also provided.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Compositions and methods for treating a range of Central Nervous System (CNS) disorders and diseases such as amyloidosis, protein folding diseases, tauopathy, and specifically Alzheimer's Disease and Parkinson's Disease, among others, in humans and in veterinary animals, by administering to a subject in need thereof a formulation comprising of melatonin, curcumin, and cannabis, specifically THC alone or with CBD.

Generally, the inventive technology relates to systems, methods, and compositions to formulate short-chain fatty acid phenolic compounds, such as cannabinoids, terpenes and other volatile compounds found in cannabinoid-producing plants such as Cannabis. In one embodiment, a natural or treated aloe vera extract may act as a cannabinoid-carrier and/or solubilizing agent forming one or more cannabinoid-infused aloe vera extract compositions, generally referred to herein as a composition or formulation of the invention. In one preferred aspect, the formulations and compositions of the invention may include safer and more palatable cannabinoid-delivery methods for both medicine and recreation. The formulations and compositions of the invention may further exhibit enhanced pharmacokinetic properties, such as enhanced bioavailability and increase adsorption in the gastrointestinal system.

The current methods and compositions provide for a novel and effective therapeutic method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain. Accordingly, certain aspects of the disclosure relate to a method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain in a subject, the method comprising administering at least one purified cannabinoid compound and a partial opioid agonist. In some embodiments, the method comprises administering a composition comprising cannabidiol and buprenorphine.

Provided herein, is a method for cancer therapy through the administration of pharmaceutical compositions comprising cannabis-specific flavonoids such as cannflavins. The flavonoids provided herein, inhibit Trk inhibitory activity therefore can be therapeutically effective for treating RTK/Trk-associated cancers. Also provided is a pharmaceutical or natural health product comprising cannflavin A and/or cannflavin B and/or cannflavin C for treating and/or preventing cancer. Such cancers are brain cancer, breast cancer, colorectal cancer, prostate cancer, pancreas cancer, ovarian cancer, lung cancer, bladder cancer, melanoma, thyroid cancer, head and neck cancers, uterine sarcoma, and/or neuroblastoma adrenocortical carcinoma.